Savara Inc quarterly report, Q1 FY2012

Full document

Business context and reporting period

The supplied filing is ADVENTRX Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2012—not a filing under the name Savara Inc. ADVENTRX was a development-stage biopharmaceutical company focused primarily on ANX-188, with ANX-514 also in development. It had no product sales and no quarterly revenue.

Financial results and liquidity

  • Revenue: $0 for Q1 2012 and Q1 2011. Gross margin was not meaningful because there were no sales.
  • Operating expenses were $4.17 million, up from $2.99 million. R&D was $2.21 million versus $0.61 million; SG&A was $2.05 million versus $1.57 million. Transaction-related expense was a $114,388 credit, compared with $799,505 expense.
  • Net loss applicable to common stock was $4.15 million, or $0.09 per share, versus $2.96 million, or $0.13 per share. The loss increased in dollars while loss per share declined, partly reflecting a higher weighted-average share count.
  • Operating cash use was $4.41 million, versus $2.38 million. Investing activities used $4.06 million, primarily reflecting purchases of certificates of deposit and property and equipment. Financing activities used $47,742; the prior-year quarter included $21.0 million net proceeds from an equity financing.
  • Cash and cash equivalents were $35.05 million and short-term investments were $11.00 million at March 31, 2012, totaling approximately $46.05 million, down from $50.70 million at December 31, 2011. Short-term investments consisted primarily of FDIC-insured certificates of deposit.
  • Total assets were $57.51 million; current liabilities were $1.95 million and total liabilities were $4.55 million, including a $2.61 million deferred tax liability. The balance sheet reports no outstanding debt balance. Stockholders’ equity was $52.96 million.

Material changes versus the prior comparable period

Quarterly R&D expense rose $1.60 million, mainly from ANX-188 and ANX-514 research-related manufacturing, increased headcount, and ANX-188 clinical consulting. SG&A increased $0.47 million, primarily from personnel and share-based compensation. Net loss widened by $1.20 million, while operating cash use increased by $2.03 million. The share count used for EPS rose from 22.76 million to 47.72 million weighted-average shares.

Outlook, risks, contingencies and unusual items

  • Management expected available cash and short-term investments to fund currently planned operations for at least 12 months, but also expected significant and increasing losses and stated that additional financing would be needed. Future funding availability and terms were uncertain.
  • ADVENTRX planned to initiate an ANX-188 Phase 3 study for sickle cell disease in 2012, subject to finalizing trial design and manufacturing clinical-trial material. It also planned smaller studies. It did not plan ANX-514 clinical studies in 2012 and was pursuing partnering options; discontinuation remained possible.
  • The SynthRx acquisition consideration includes shares subject to repurchase and milestone shares tied to ANX-188 development and regulatory milestones. Quarterly remeasurement produced a net $0.1 million reduction in transaction-related expense. The associated contingent asset and liability rely on Level 3 estimates and stock-price assumptions.
  • A completed tax study identified ownership changes under IRC Sections 382 and 383. The company said it might be unable to use tax attributes accumulated through November 11, 2011; the related valuation allowance adjustment had no income-tax impact.
  • Key risks include clinical and regulatory failure or delay, reliance on third-party manufacturers and CROs, future financing and dilution, and dependence on ANX-188. The filing also describes prior FDA setbacks for Exelbine and an unsuccessful ANX-514 bioequivalence study. Disclosure controls were assessed as effective; no material change in internal control over financial reporting was reported.

Important facts for investors to verify

  1. Confirm the issuer’s identity: the supplied document names ADVENTRX Pharmaceuticals, Inc., despite the request metadata naming Savara Inc.
  2. Check whether the planned 2012 ANX-188 Phase 3 study began as intended, and review trial design, manufacturing readiness, safety, efficacy, and regulatory developments.
  3. Assess cash runway against actual development spending and financing needs; do not treat potential warrant proceeds as assured.
  4. Review the assumptions and potential share dilution from SynthRx milestone consideration, as well as restrictions on use of tax attributes.
  5. Verify subsequent changes in product strategy, partnering, listing status, and any financing that could materially change the risk profile.